A new study, published in The Korean Journal of Internal Medicine, sought to identify the factors associated with time to diagnosis of early RA after the onset of symptoms, and found that older age, higher educational level, higher income, and small joint involvement were all positive factors for early diagnosis of RA.
Early diagnosis and treatment can lead to better outcomes for patients with rheumatoid arthritis (RA). A new study, published in The Korean Journal of Internal Medicine, sought to identify the factors associated with time to diagnosis of early RA after the onset of symptoms, and found that older age, higher educational level, higher income, and small joint involvement were all positive factors for early diagnosis of RA.
The study, conducted in Korean patients over 18 years of age who satisfied the American College of Rheumatology’s classification criteria for RA and who had a disease duration of 1 year or less were recruited for participation in the study across 23 centers in the Republic of Korea. In total, 714 patients with early RA were included in the analysis; 56% (n = 401) were classified as having been diagnosed early, and 44% (n = 313) were classified as having been diagnosed late.
Patients in the study completed an initial questionnaire that established their demographic profile, socioeconomic status, and disease-specific outcome. Data collected included age at symptom onset, disease duration, and inflammatory markers as well as family type, income and educational level, and comorbidities.
The researchers found that an older age at symptom onset (odds ratio [OR], 1.03; 95% CI, 1.02-1.05), a higher level of education (OR, 1.68; 95% CI, 1.14-2.47), a higher income level (OR, 1.48; 95% CI, 1.05-2.08) and initial small joint involvement (OR, 1.42; 95% CI, 1.02-1.98) were associated with early diagnosis in patients with early RA.
The researchers further divided the patients into 2 groups: patients who were older (aged 60 or over) at the onset of RA or younger (aged younger than 60). In the younger-onset group, an older age at symptom onset (OR, 1.03; 95% CI, 1.01-1.05), a higher level of education (OR, 1.66; 95% CI, 1.07-2.58) and higher income (OR, 1.47; 95% CI, 1.01-2.15) were predictive factors for early diagnosis, but there were no predictive factors identified in the older onset group.
The authors concluded that, even in the Republic of Korea, which had good access to healthcare, delays are present in the diagnosis of RA, especially for patients with low education, a young age, or involvement of a large joint.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More